HIV/AIDS Therapy
20 mg/kg of amprenavir twice daily is safe for HIV-infected children
Published in AIDS Weekly, April 4th, 2005
"A phase I, open-label, dose-escalating trial was conducted to evaluate the safety, tolerability, and pharmacokinetics of single, oral doses of amprenavir (141W94), a potent inhibitor of human immunodeficiency virus type 1 (HIIV-1) protease, in 20 HIV-infected children 4 to 12 years of age.
"The doses of amprenavir evaluated, 5, 10, 15, and 20 mg/kg of body weight, were comparable to those evaluated in adult phase I and II studies. The most common clinical adverse event associated with amprenavir, administered as soft gelatin capsules, was nausea," scientists in the United States...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-04-04)
More Articles from AIDS Weekly
- HIV/AIDS Drug Development
PNA-transportan conjugate targeted to HIV-1 TAR is antiviral and virucidal - HIV/AIDS Infection
Amphotericin-B reactivates latent HIV-1 infection - HIV/AIDS Lipodystrophy
VLDL elevation in early HAART therapy caused by impaired VLDL clearance - HIV/AIDS Therapy
IL-16 levels increase after structured intermittent HAART interruption - Awards
GlaxoSmithKline CEO Jean-Pierre Garnier gets Global Business Leadership award - Business Update
Medical services company extends distribution over 10 Chinese provinces - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
